Resistant arterial hypertension: modern view of the problem

Abstract

In clinical practice, uncontrolled arterial hypertension remains a difficult but solvable task, given the available arsenal of antihypertensive drugs. However, resistant arterial hypertension is diagnosed in 10%–15% of these cases. A significantly higher risk of cardiovascular complications indicates the extreme importance of the successful treatment of this pathology. Resistant hypertension is defined as above-goal high blood pressure in a patient despite concurrent use of three antihypertensive drug classes, commonly including a long-acting calcium channel blocker, a renin–angiotensin blocker (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. All antihypertensive drugs should be administered at maximum or maximally tolerated doses. Resistant hypertension also includes cases in which blood pressure targets are achieved with ≥4 antihypertensive medications. The diagnosis of resistant hypertension requires assurance of antihypertensive medication adherence and exclusion of the “white-coat effect” (office blood pressure above goal but out-of-office blood pressure at or below the target). Once antihypertensive medication adherence is confirmed and out-of-office blood pressure recordings exclude a white-coat effect, the evaluation includes the identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. The management of resistant hypertension includes the maximization of lifestyle interventions, correction of sleep disorders, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower blood pressure if blood pressure remains high.

Keywords

sleep apnea / obstructive / white coat hypertension, combined antihypertensive therapy, uncontrolled arterial hypertension / obesity / patient compliance / resistant arterial hypertension / renin-angiotensin system / ambulatory blood pressure monitoring

References

[1] Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). DOI: 10.15829/1560-4071-2020-3-3786

[2] Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. T. 25, № 3. С. 3786. DOI: 10.15829/1560-4071-2020-3-3786

[3] Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–e90. DOI: 10.1161/HYP.0000000000000084

[4] Carey R.M., Calhoun D.A., Bakris G.L., et al. Resistant hypertension: detection, evaluation, and management a scientific statement from the American Heart Association // Hypertension. 2018. Vol. 72, No. 5. P. e53–e90. DOI: 10.1161/HYP.0000000000000084

[5] Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98–105. DOI: 10.1136/heartjnl2018-313599

[6] Noubiap J.J., Nansseu J.R., Nyaga U.F., et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients // Heart. 2019. Vol. 105, No. 2. P. 98–105. DOI: 10.1136/heartjnl2018-313599

[7] Bangalore S, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT. The American Journal of Medicine. 2017;130(4):439–448.e9. DOI: 10.1016/j.amjmed.2016.10.002

[8] Bangalore S., Davis B.R., Cushman W.C., et al. Treatment-resistant hypertension and outcomes based on randomized treatment group in ALLHAT // The American Journal of Medicine. 2017. Vol. 130, No. 4. P. 439–448.e9. DOI: 10.1016/j.amjmed.2016.10.002

[9] Frohlich E.D. Classification of resistant hypertension. Hypertension. 1988;11(3 Pt 2):67–70. DOI: 10.1161/01.hyp.11.3_pt_2.ii67

[10] Frohlich E.D. Classification of resistant hypertension // Hypertension. 1988. Vol. 11, No. 3 Pt. 2. P. 67–70. DOI: 10.1161/01.hyp.11.3_pt_2.ii67

[11] Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019;37(9):1797–1804. DOI: 10.1097/HJH.0000000000002103

[12] Buhnerkempe M.G., Botchway A., Prakash V., et al. Prevalence of refractory hypertension in the United States from 1999 to 2014 // J Hypertens. 2019. Vol. 37, No. 9. P. 1797–1804. DOI: 10.1097/HJH.0000000000002103

[13] Chedier B, Cortez AF, Roderjan CN, et al. Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension. J Hum Hypertens. 2021;35(8):709–717. DOI: 10.1038/s41371-020-00406-2

[14] Chedier B, Cortez AF, Roderjan CN, et al. Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension // J Hum Hypertens. 2021. Vol. 35, No. 8. P. 709–717. DOI: 10.1038/s41371-020-00406-2

[15] Kuzmin O.B., Zhezha V.V., Buchneva N.V., Landar L.N. refractory arterial hypertension: hyperactivity of the sympathetic nervous system, kidney and approaches to antihypertensive drug therapy. Arterial’naya Gipertenziya. 2022;28(5):600–608. (In Russ.). DOI: 10.18705/1607-419X-2022-28-5-600-608

[16] Кузьмин О.Б., Жежа В.В., Бучнева Н.В., и др. Рефрактерная артериальная гипертензия: гиперактивность симпатической нервной системы, почка и подходы к повышению клинической эффективности антигипертензивной лекарственной терапии // Артериальная гипертензия. 2022. Т. 28, № 5. С. 600–608. DOI: 10.18705/1607-419X-2022-28-5-600-608

[17] Eskаs PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205. DOI: 10.3109/08037051.2015.1121706

[18] Eskas P.A., Heimark S., Eek Mariampillai J., et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension // Blood Press. 2016. Vol. 25, No. 4. P. 199–205. DOI: 10.3109/08037051.2015.1121706

[19] Вerra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. J Hypertension. 2016;68(2):297–306. DOI: 10.1161/HYPERTENSIONAHA.116.07464

[20] Berra E., Azizi M., Capron A., et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension // J Hypertension. 2016. Vol. 68, No. 2. P. 297–306. DOI: 10.1161/HYPERTENSIONAHA.116.07464

[21] Cuspidi C, Sala C, Tadic M, et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review. J Clin Hypertens (Greenwich). 2017;19(7): 713–721. DOI: 10.1111/jch.13023

[22] Cuspidi C., Sala C., Tadic M., et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review // J Clin Hypertens (Greenwich). 2017. Vol. 19, No. 7. P. 713–721. DOI: 10.1111/jch.13023

[23] Shallcross AJ, Butler M, Tanner RM, et al. Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study. J Hum Hypertens. 2017;31(7):474–478. DOI: 10.1038/jhh.2016.100

[24] Shallcross A.J., Butler M., Tanner RM., et al. Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study // J Hum Hypertens. 2017. Vol. 31, No. 7. P. 474–478. DOI: 10.1038/jhh.2016.100

[25] Hoffmann TJ, Ehret GB, Nandakumar P, et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. Nat Genet. 2017;49(1):54–64. DOI: 10.1038/ng.3715

[26] Hoffmann T.J., Ehret G.B., Nandakumar P., et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation // Nat Genet. 2017. Vol. 49, No. 1. P. 54–64. DOI: 10.1038/ng.3715

[27] Ostroumova OD, Kulikova MI. Drug-induced arterial hypertension. Systemic Hypertension. 2019;16(2):32–41. (In Russ.). DOI: 10.26442/2075082X.2019.2.1801642019

[28] Остроумова О.Д., Куликова М.И. Лекарственно-индуцированная артериальная гипертония // Системные гипертензии. 2019. Т. 16, № 2. С. 32–41. DOI: 10.26442/2075082X.2019.2.1801642019

[29] Karateev AE. Destabilized hypertension as a complication of therapy with nonsteroidal anti-inflammatory drugs: the importance of the problem. Modern Rheumatology Journal. 2018;12(2):64–72. (In Russ.). DOI: 10.14412/1996-7012-2018-2-64-72

[30] Каратеев А.Е. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы // Современная ревматология. 2018. Т. 12, № 2. С. 64–72. DOI: 10.14412/1996-7012-2018-2-64-72

[31] Afshari M, Alizadeh-Navaei R, Moosazadeh M. Oral contraceptives and hypertension in women: results of the enrolment phase of Tabari Cohort Study. BMC Womens Health. 2021;21(1):224. DOI: 10.1186/s12905-021-01376-4

[32] Afshari M., Alizadeh-Navaei R., Moosazadeh M. Oral contraceptives and hypertension in women: results of the enrolment phase of Tabari Cohort Study // BMC Womens Health. 2021. Vol. 21, No. 1. P. 224. DOI: 10.1186/s12905-021-01376-4

[33] Brar SK, Perveen S, Chaudhry MR, et al. Erythropoietin-induced hypertension: a review of pathogenesis, treatment, and role of blood viscosity. Cureus. 2021;13(1):12804. DOI: 10.7759/cureus.12804

[34] Brar S.K., Perveen S., Chaudhry M.R., et al. Erythropoietin-induced hypertension: a review of pathogenesis, treatment, and role of blood viscosity // Cureus. 2021. Vol. 13, No. 1. P. 12804. DOI: 10.7759/cureus.12804

[35] Krasińska B, Miazga A, Cofta S, et al. Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. Pol Arch Med Wewn. 2016;126(5):330–339. DOI: 10.20452/pamw.3410

[36] Krasińska B., Miazga A., Cofta S., et al. Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension // Pol Arch Med Wewn. 2016. Vol. 126, No. 5. P. 330–339. DOI: 10.20452/pamw.3410

[37] Jehan S, Zizi F, Pandi-Perumal SR, et al. Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease. Sleep Med Disord. 2020;4(3):67–76. DOI: 10.15406/smdij.2020.04.00076

[38] Jehan S., Zizi F., Pandi-Perumal S.R., et al. Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease // Sleep Med Disord. 2020. Vol. 4, No. 3. P. 67–76. DOI: 10.15406/smdij.2020.04.00076

[39] Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–1302. DOI: 10.1097/HJH.0000000000002843

[40] Stergiou G.S., Palatini P., Parati G., et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement // J Hypertens. 2021. Vol. 39, No. 7. Р. 1293–1302. DOI: 10.1097/HJH.0000000000002843

[41] Rodionov AV, Yudin IG, Fomin VV. Resistant arterial hypertension. Consilium Medicum. 2021;23(1):8–31. (In Russ.). DOI: 10.26442/20751753.2021.1.200697

[42] Родионов А.В., Юдин И.Г., Фомин В.В. Резистентная артериальная гипертензия // Consilium Medicum. 2021. Т. 23, № 1. C. 28–31. DOI: 10.26442/20751753.2021.1.200697

[43] Correa NB, de Faria AP, Ritter AM, et al. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016;10(6): 510–516.e1. DOI: 10.1016/j.jash.2016.03.194

[44] Correa N.B., de Faria A.P., Ritter A.M., et al. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension // J Am Soc Hypertens. 2016. Vol. 10, No. 6. P. 510–516.e1. DOI: 10.1016/ j.jash.2016.03.194

[45] Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am. 2017;101:229–245. DOI: 10.1016/j.mcna.2016.08.005

[46] Peacock E., Krousel-Wood M. Adherence to antihypertensive therapy // Med Clin North Am. 2017. Vol. 101. P. 229–245. DOI: 10.1016/j.mcna.2016.08.005

[47] Dassanayake S, Sole G, Wilkins G, et al. Effectiveness of physical activity and exercise on ambulatory blood pressure in adults with resistant hypertension: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev. 2022;29(3):275–286. DOI: 10.1007/s40292-022-00517-6

[48] Dassanayake S., Sole G., Wilkins G., et al. Effectiveness of physical activity and exercise on ambulatory blood pressure in adults with resistant hypertension: a systematic review and meta-analysis // High Blood Press Cardiovasc Prev. 2022. Vol. 29, No. 3. P. 275–286. DOI: 10.1007/s40292-022-00517-6

[49] Kruk PJ, Nowicki M. Effect of the physical activity program on the treatment of resistant hypertension in primary care. Prim Health Care Res Dev. 2018;19(6):575–583. DOI: 10.1017/S1463423618000154

[50] Kruk P.J., Nowicki M. Effect of the physical activity program on the treatment of resistant hypertension in primary care // Prim Health Care Res Dev. 2018. Vol. 19, No. 6. P. 575–583. DOI: 10.1017/S1463423618000154

[51] Kuchmin AN, Ekimov VV, Galaktionov DA, et al. Blood pressure profiles in patients with arterial hypertension and obstructive sleep apnea in different age groups. Arterial’naya Gipertenziya. 2021;27(5): 530–535. (In Russ.). DOI: 10.18705/1607-419X-2021-27-5-530-535

[52] Кучмин А.Н., Екимов В.В., Галактионов Д.А., и др. Суточные профили артериального давления у больных с артериальной гипертензией и синдромом обструктивного апноэ во время сна в различных возрастных группах // Артериальная гипертензия. 2021. Т. 21, № 5. С. 530–535. DOI: 10.18705/1607-419Х-2021-27-5-530-535

[53] Jaffe MG, Young JD. The Kaiser Permanente Northern California Story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich). 2016;18:260–261. DOI: 10.1111/jch.12803

[54] Jaffe M.G., Young J.D. The Kaiser Permanente Northern California Story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013) // J Clin Hypertens (Greenwich). 2016. Vol. 18. P. 260–261. DOI: 10.1111/jch.12803

[55] Kryukov EV, Potekhin NP, Fursov AN, et al. Arterial hypertension and atherosclerosis: evaluation of the effectiveness of antihypertensive therapy. Medical Bulletin of the Main Military Clinical Hospital named after N.N. Burdenko. 2020(1):5–10. (In Russ.).

[56] Крюков Е.В., Потехин Н.П., Фурсов А.Н., и др. // Артериальная гипертензия и атеросклероз: оценка эффективности антигипертензивной терапии // Медицинский вестник ГВКГ им. Н.Н. Бурденко. 2020. № 1. С. 5–10.

[57] Krieger EM, Drager LF, Giorgi DMA, et al. spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681–690. DOI: 10.1161/H

[58] Krieger E.M., Drager L.F., Giorgi D.M.A., et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment) // Hypertension. 2018. Vol. 71, No. 4. P. 681–690. DOI: 10.1161/HYPERTENSIONAHA.117.10662

[59] Kario K, Bhatt DL, Kandzari DE, et al. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension: insights from the SYMPLICITY HTN-3 trial. Circ J. 2016;80(6): 1404–1412. DOI: 10.1253/circj.0035

[60] Kario K., Bhatt D.L., Kandzari D.E., et al. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension: insights from the SYMPLICITY HTN-3 trial // Circ J. 2016. Vol. 80, No. 6. P. 1404–1412. DOI: 10.1253/circj. 0035

[61] Wilson AL, Gandhi J, Suh Y, et al. Renal Innervation in resistant hypertension: a review of pathophysiology and renal denervation as potential treatment. Curr Hypertens Rev. 2020;16(2):115–127. DOI: 10.2174/1573402115666190301154100

[62] Wilson A.L., Gandhi J., Suh Y., et al. Renal innervation in resistant hypertension: a review of pathophysiology and renal denervation as potential treatment // Curr Hypertens Rev. 2020. Vol. 16, No. 2. P. 115–127. DOI: 10.2174/1573402115666190301154100

[63] Bhatt DL, Kandzari DE, O’Neill WW, et al. For the SYMPLICITY HTN-3 investigators: a controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401. DOI: 10.1056/NEJMoa1402670

[64] Bhatt D.L., Kandzari D.E., O’Neill W.W., et al. For the SYMPLICITY HTN-3 investigators: a controlled trial of renal denervation for resistant hypertension // N Engl J Med. 2014. Vol. 370, No. 15. P. 1393–1401. DOI: 10.1056/NEJMoa1402670

[65] de Leeuw PW, Bisognano JD, Bakris GL, et al. Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up. Hypertension. 2017;69(5):836–843. DOI: 10.1161/HYPERTENSIONAHA.117.09086

[66] de Leeuw P.W., Bisognano J.D., Bakris G.L., et al. Sustained reduction of blood pressure with baroreceptor activation therapy: Results of the 6-year open follow-up // Hypertension. 2017. Vol. 69, No. 5. P. 836–843. DOI: 10.1161/HYPERTENSIONAHA.117.09086

[67] Spiering W, Williams B, Van der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390(10113):2655–2661. DOI: 10.1016/S0140-6736(17)32337-1

[68] Spiering W., Williams B., Van der Heyden J., et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study // Lancet. 2017. Vol. 390, No. 10113. P. 2655–2661. DOI: 10.1016/S0140-6736(17)32337-1

[69] Elijovich F, Weinberger MH, Anderson CA, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68(3):7–46. DOI: 10.1161/HYP.0000000000000047

[70] Elijovich F., Weinberger M.H., Anderson C.A., et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association // Hypertension. 2016. Vol. 68, No. 3. P. 7–46. DOI: 10.1161/HYP.0000000000000047

[71] Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395–405. DOI: 10.1056/NEJMoa2213169

[72] Freeman M.W., Halvorsen Y.D., Marshall W., et al. Phase 2 trial of Baxdrostat for treatment-resistant hypertension // N Engl J Med. 2023. Vol. 388, No. 5. P. 395–405. DOI: 10.1056/NEJMoa2213169

[73] Azizi M, Rossignol Р, Hulot JS. Emerging drug classes and their potential use in hypertension. Hypertension. 2019;74(5):1075–1083. DOI: 10.1161/HYPERTENSIONAHA.119.12676

[74] Azizi M., Rossignol Р., Hulot J.S. Emerging drug classes and their potential use in hypertension // Hypertension. 2019. Vol. 74, No. 5. P. 1075–1083. DOI: 10.1161/HYPERTENSIONAHA.119.12676

[75] Kida Y. Baxdrostat for treatment-resistant hypertension. Engl J Med. 2023;388(19):1820–1822. DOI: 10.1056/NEJMc2302673

[76] Kida Y. Baxdrostat for treatment-resistant hypertension // N Engl J Med. 2023.Vol. 388, No. 19. P. 1820–1822. DOI: 10.1056/NEJMc2302673

[77] Angeli F, Verdecchia P, Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Cardiol Ther. 2021;10(2):397–406. DOI: 10.1007/s40119-021-00233-7

[78] Angeli F., Verdecchia P., Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension // Cardiol Ther. 2021. Dec. Vol. 10, No. 2. P. 397–406. DOI: 10.1007/s40119-021-00233-7

[79] Leopold JA, Ingelfinger JR. Aldosterone and treatment-resistant hypertension. N Engl J Med. 2023;388(5):464–467. DOI: 10.1056/NEJMe2213559

[80] Leopold J.A., Ingelfinger J.R. Aldosterone and treatment-resistant hypertension // N Engl J Med 2023. Vol. 388, No. 5. P. 464–467. DOI: 10.1056/NEJMe2213559

[81] Khugaeva EV. Remote monitoring of blood pressure as an element of personalized medicine. International Journal of Advanced Studies in Medicine and Biomedical Sciences. 2023;1:68–79. (In Russ.).

[82] Хугаева Э.В. Дистанционное мониторирование артериального давления как элемента персонализированной медицины // International Journal of Advanced Studies in Medicine and Biomedical Sciences. 2023. № 1. С. 68–79.

RIGHTS & PERMISSIONS

Eco-Vector